The Putative Association of TOB1 - AS1 Long Non-coding RNA with Immune Tolerance: A Study on Multiple Sclerosis Patients
In this study, 39 MS patients and 32 healthy matched controls were recruited. Real-time PCR standard curve method was used to quantify transcript levels ofTOB1-AS1, TOB1, SKP2, andTSG. In addition, the potential sex hormone receptor binding sites on target genes promoter were analyzed using JASPR software. This work demonstrates a negative correlation betweenTOB1-AS1 expression and EDSS of patients. Also, a robust dysregulation of co-expression ofTOB1-AS1 lncRNA and the coding genes in MS patients compared to controls was observed. Such dysregulation in this pathway may be related to MS pathogenesis and response to interferon treatment.
Publication date: Available online 27 March 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Gavin Giovannoni, Chris Hawkes, Jeannette Lechner-Scott, Michael Levy, Emmanuelle Waubant, Julian Gold
Publication date: Available online 27 March 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Christopher H. Hawkes, Gavin Giovannoni, Michael Levy, Jeanette Lechner-Scott, Emmanuelle Waubant
The oral immunomodulator is indicated for treatment of adults with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.Medscape Medical News
This study discusses the rare possible etiologies of USNHL that can be easily missed if these are not ruled out properly. We present these cases to consider these heterogeneous and distinct ca uses of USNHL because of rarity of these etiologies. If such an etiology is diagnosed in time, they may be managed effectively.
Ozanimod is the first oral, once-daily sphingosine-1-phosphate receptor modulator approved for adults with relapsing forms of multiple sclerosis.
Publication date: Available online 26 March 2020Source: Annals of Physical and Rehabilitation MedicineAuthor(s): Sophie Jacquin-Courtois, Philippe Azouvi, Dominic Pérennou
Condition: Multiple Sclerosis Interventions: Other: Mental practice; Other: Mental practice + skill training; Other: Control group Sponsor: Cristina García-Bravo Completed
ConclusionOur data confirmed that a high percentage of patients shift to or remain in a positive JCV status during NTZ treatment and after discontinuation. NTZ suspension seems not to be able to interfere on JCV status modification over an extended period. The choice of alternative treatment as exit strategy after NTZ discontinuation should be carefully considered because it could negatively influence the PML risk stratification of patients.
AbstractObjectiveMultiple Sclerosis (MS) is one of the most common neurological diseases in the world. Due to structural and functional changes in central nerves system, the patients with MS may affected by sensory-motor learning deficits. The aims of the current study was to assess the effect of primary motor cortex (M1) anodal transcranial direct current stimulation (a-tDCS) on online and offline motor learning in patients with MS.Materials and methodsThirty-nine patients with MS were randomly assigned in three groups: concurrent M1 a-tDCS and serial response time test (SRTT) (n=13), concurrent sham a-tDCS and SRTT (n=13...
Dimethyl Fumarate (DMF), known for its mechanism of action targeting Nrf2 and related redox homeostasis, is an approved immunotherapy for patients with Multiple Sclerosis (PwMS) in the relapsing form. We assessed how DMF modulates immune cell functions, namely the cytokine profile of co-cultured B and T cells, and the chemokine-mediated migration of immune cells. Following DMF therapy, LT α+, TNFα+ and IFNγ+ B cells were reduced while TGFβ and IL10 expression elevated. B cells from DMF-treated patients increased TGFβ and LTα expression on T cells, while DMF directly reduced TNFα+ and...